Market News
North America Sickle Cell Disease Market: Key Developments
- In October 2022, Pfizer Inc., a U.S.-based multinational pharmaceutical and biotechnology corporation, announced the completion of its acquisition of Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities starting with Sickle Cell Disease (SCD). The acquisition reinforces Pfizer’s commitment to SCD, building on a 30-year legacy in the rare hematology space.
- In July 2022, Global Blood Therapeutics, Inc. announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Great Britain marketing authorization for Oxbryta (voxelotor) for the treatment of hemolytic anemia due to Sickle Cell Disease (SCD) in adult and pediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide (hydroxyurea). Voxelotor, an oral treatment taken once daily, is the first medicine authorized in Great Britain that directly inhibits sickle hemoglobin (HbS) polymerization, the molecular basis of sickling, and the destruction of red blood cells in SCD.
- In May 2021, Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced that the U.S. Food and Drug Administration (FDA) has approved FERRIPROX (deferiprone) for the treatment of transfusional iron overload due to Sickle Cell Disease (SCD) or other anemias in adult and pediatric patients 3 years of age and older. This U.S. FDA approval expands the use of FERRIPROX for patients with SCD or other anemias as well as patients with thalassemia, regardless of prior iron chelation exposure.
U.S.: 
U.K. : 
India : 
